

The changes of corneal biomechanical properties with long-term treatment of prostaglandin analogue measured by Corvis ST

Na Wu

Eye & ENT Hospital of Fudan University

Yuhong Chen (✉ yuhongchen@fudan.edu.cn)

Yaping Yang

Eye and ENT Hospital of Fudan University

Xinghuai Sun

Eye and ENT Hospital of Fudan University

Research article

Keywords: prostaglandin analogue, corneal biomechanical properties, glaucoma, Corvis ST

Posted Date: June 22nd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-22280/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on October 20th, 2020. See the published version at <https://doi.org/10.1186/s12886-020-01693-6>.

Abstract

Background: To investigate the corneal biomechanical changes in primary open angle glaucoma (POAG) patients treated with long-term prostaglandin analogue (PGA).

Methods: 111 newly diagnosed POAG patients, including 43 high tension glaucoma (HTG) and 68 normal tension glaucoma (NTG), were measured by Corvis ST to obtain intraocular pressure (IOP), central corneal thickness (CCT) and corneal biomechanical parameters at baseline and at each follow-up visit after initiation of PGA treatment. The follow-up measurements were analyzed by the generalized estimate equation model with an exchangeable correlation structure. Restricted cubic spline was employed to estimate the dose-response relation between follow-up time and corneal biomechanics.

Results: The mean follow-up time was 10.3 ± 7.02 months. Deformation amplitude (DA, $\beta = -0.0015$, $P = 0.016$), the first applanation velocity (AV1, $\beta = -0.0004$, $P = 0.00058$) decreased and the first applanation time (AT1, $\beta = 0.0089$, $P < 0.000001$) increased statistically significantly with PGA therapy over time after adjusting for age, gender, axial length, corneal curvature, IOP and CCT. In addition, AT1 was lower (7.2950 ± 0.2707 in NTG and 7.5889 ± 0.2873 in HTG, $P = 0.00011$) and AV1 was greater (0.1478 ± 0.0187 in NTG and 0.1314 ± 0.0191 in HTG, $P = 0.00002$) in NTG than in HTG after adjusting for confounding factors.

Conclusions: Chronic use of PGA probably could influence the corneal biomechanical properties directly, which is to make cornea less deformable. Besides, corneas in NTG tended to be more deformable compared to those in HTG with long-term treatment of PGA.

Background

Corneal biomechanical properties have recently attracted increasing attention for its involvement in glaucoma and in other ocular diseases, such as keratoconus[1]. The biomechanical properties of cornea may determine its deformation response to applanation, which influences the intraocular pressure (IOP) measurement[2, 3]. In addition, it has been speculated that corneal biomechanics may represent structural vulnerabilities of the whole eyeball to the development of glaucoma[4-6]. Thus, understanding corneal biomechanics is helpful to improve the diagnosis and management of glaucoma[2, 3, 7].

Primary open angle glaucoma (POAG) is the most common type of glaucoma worldwide. Prostaglandin analogue (PGA) is the first-line hypotensive medication for POAG currently. Long-term use of PGA has been reported to decrease the central corneal thickness (CCT) due to activation of corneal stromal matrix metalloproteinases (MMPs)[8, 9]. Experimental studies also indicate that PGA causes morphological and biochemical changes of corneal stroma[10]. These changes imply that corneal biomechanical properties could possibly be affected by PGA.

Most of the available studies about corneal biomechanics were conducted by using the Ocular Response Analyzer (ORA)[11]. ORA is the first developed device, which is able to provide an *in vivo* measurement of corneal viscoelastic parameter called corneal hysteresis (CH)[12]. CH is shown to be

decreased in glaucomatous eyes compared to that in normal controls[13] and associated with visual field progression in glaucomatous eyes[7].

The Corneal Visualization Scheimpflug Technology (Corvis ST) is a newly available non-touch instrument that provides precise, repeatable, and reproducible measurements of corneal biomechanics *in vivo*[11, 14]. The Corvis ST uses an ultra-high-speed Scheimpflug camera to record corneal deformation in real time and provides direct information on corneal biomechanical behavior[15] and could potentially provide more information on corneal biomechanics than ORA[16].

Our previous study conducted by Corvis ST observed significant differences in biomechanical parameters between treatment naïve POAG patients and patients with long-term therapy of PGA, even after adjusting for other confounding factors that might influence biomechanics, such as IOP and CCT[17]. The results suggested that PGA might have a potential effect on corneal biomechanical properties in addition to its indirect effect owing to IOP decrease and CCT reduction[17]. However, due to the cross-sectional design, the influence of PGA on corneal biomechanics remains unanswered. In this study, we prospectively followed up newly diagnosed POAG patients under PGA treatment to observe the changes of corneal biomechanical properties over time.

Methods

This research was approved by the Medical Ethics Committee of Eye and ENT Hospital of Fudan University, and adhered to the Declaration of Helsinki. Written informed consents were obtained from all of the participants.

Patients who were newly diagnosed with POAG were recruited consecutively at Eye and ENT Hospital of Fudan University. POAG was diagnosed with the criteria as follows: an open anterior chamber angle on gonioscopy examination, characteristic glaucomatous optic disc changes (thinning of the optic disc rim and/or enlargement of the optic disc cupping) with corresponding visual field defects: (1) glaucoma hemifield test values outside the normal limits; or (2) three or more abnormal points with a probability of being normal of $P < 5\%$, of which at least one point has a pattern deviation of $P < 1\%$; or (3) a pattern standard deviation of $P < 5\%$. In addition, patients were diagnosed with high tension glaucoma (HTG) when they had at least one measurement of $IOP > 21\text{mmHg}$ with a Goldmann applanation tonometer. Patients diagnosed as normal tension glaucoma (NTG) had an $IOP \leq 21\text{mmHg}$ at all time points on a 24-hour IOP variation test. Patients who received continuous therapy of only one type of PGA medication were enrolled in the study. Exclusion criteria included any coexisted ocular conditions such as corneal diseases, previous history of ocular laser or surgical treatment, which might affect corneal biomechanics. Secondary glaucoma, such as trauma, uveitis and steroid induced glaucoma, was excluded as well.

All participants underwent a comprehensive ophthalmologic examination when they were first enrolled in the study, including best corrected visual acuity, slit-lamp biomicroscopy, fundus evaluation with a 90D lens, gonioscopy examination, automated perimetry (Humphrey Field Analyzer, Carl Zeiss, USA) and the

retinal nerve fiber layer thickness on optical coherence tomography (OCT) (Optovue RTVue OCT, USA). Axial length and corneal curvature were measured by IOL Master (Zeiss, Germany).

The Corvis ST (Oculus, GmbH, Wetzlar, Germany) not only measures IOP, biomechanically corrected IOP (bIOP), CCT, but also provides parameters of corneal biomechanical properties by exerting an air impulse on the cornea. Under the pressure, the cornea bends inward from the resting state to the first applanation point and continues to move until reaches the maximum deformation state, namely highest concavity (HC). When the pressure of air puff decreases, the cornea moves outward and passes the second applanation point before arriving at its resting state[11, 14]. The biomechanical parameters used in this study were: 1) time from the resting state to the first and second applanations (AT1 and AT2, respectively); 2) corneal velocity during the first and second applanations (AV1 and AV2, respectively); 3) highest concavity time (HC-time) and maximum deformation amplitude (DA) from the resting state to the HC at the corneal apex; peak distance between corneal bending points (HC-PD) and radius of curvature (HC-radius) at HC[11, 14, 18].

Patients were examined by Corvis ST at baseline and at each follow-up visit. Both eyes were included if they were eligible. Single eyes were selected on 7 patients because the other ones could not obtain reliable measurements. It should be noted that only Corvis ST measurements of post-treatment of PGA were used for statistical analysis.

Statistical analyses were performed with R 3.3 (<http://www.R-project.org>).

Descriptive statistical results were presented as the mean \pm standard deviation (SD). The repeated follow-up measurements were analyzed by the generalized estimate equation model with an exchangeable correlation structure. Restricted cubic spline was employed to estimate the dose-response relation between follow-up time and IOP, CCT and corneal biomechanical parameters with adjustment. Independent samples *t* test and chi-square test were used for comparison of demographic (age and gender) and clinical (axial length and corneal curvature) measurements between NTG and HTG groups. It was considered statistically significant if the *P* value was less than 0.05.

Results

The examined group consisted of 111 newly diagnosed POAG patients, including 43 female and 68 male with a mean age of 48.04 ± 14.14 years (22 - 82 years). Together, 215 eyes were examined (both eyes from 104 subjects and 7 eyes from 7 subjects). The mean follow-up time was 10.3 ± 7.02 months (1.15 - 41.57 months). Subjects had an average of 2.53 ± 1.42 (1-7) times of follow-up visits in the study. The mean axial length and corneal curvature of the total subjects were 25.6 ± 1.77 mm and 7.75 ± 0.24 mm, respectively (Table 1). A slight but statistically significant decrease in IOP ($\beta=-0.0596$, $P=0.000047$),

bIOP ($\beta=-0.0369$, $P=0.0029$) and CCT ($\beta=-0.6639$, $P<0.000001$) was observed during the period of PGA usage (Table 2, Fig.1).

Table 1. Demographic, clinical and diagnostic characteristics of 111 newly diagnosed primary open angle glaucoma patients participating in the study.

Category	
Age, years	48.04 \pm 14.14 (22-82)
Gender	
Female	43 (38.7%)
Male	68 (61.3%)
Follow-up period, months	10.3 \pm 7.02 (1.15 - 41.57)
Follow-up times	2.53 \pm 1.42 (1-7)
Diagnosis	
High tension glaucoma (HTG)	43 (38.7%)
Normal tension glaucoma (NTG)	68 (61.3%)
Axial length, mm	25.6 \pm 1.77
Corneal curvature, mm	7.75 \pm 0.24

Table 2. The changes of IOP, bIOP and CCT in POAG patients under PGA treatment over time.

	β	95% CI	<i>P</i> value
IOP	-0.0596	-0.0883 to -0.0309	0.000047
bIOP	-0.0369	-0.0612 to -0.0126	0.0029
CCT	-0.6639	-0.8048 to -0.5230	<0.000001

IOP: intraocular pressure; bIOP: biomechanically corrected intraocular pressure; CCT: central corneal thickness; POAG: primary open angle glaucoma; PGA: prostaglandin analogue

Generalized estimate equation model with an exchangeable correlation structure was used to observe the corneal biomechanical changes with PGA treatment over time. After adjusting for age, gender, axial length, corneal curvature, IOP and CCT, AT1 increased ($\beta=0.0089$, $P<0.000001$), whereas DA and AV1 decreased statistically significantly over time ($\beta=-0.0015$, $P=0.016$ for DA; $\beta=-0.0004$, $P=0.00058$ for AV1) (Table 3, Fig. 2). Other corneal biomechanical parameters showed no statistically significant changes over time (Table 3).

Table 3. The changes of corneal biomechanical parameters in POAG patients under PGA treatment over time with adjustment for age, gender, axial length, corneal curvature, IOP and CCT.

Corneal biomechanical parameters	After adjustment	
	β	<i>P</i> value
DA	-0.0015	0.016
AT1	0.0089	<0.000001
AV1	-0.0004	0.00058
AT2	-0.0059	0.139
AV2	0.0003	0.364
HC-time	-0.0044	0.272
HC-PD	-0.0023	0.196
HC-radius	-0.0076	0.346

POAG: primary open angle glaucoma; PGA: prostaglandin analogue; IOP: intraocular pressure; CCT: central corneal thickness; DA: deformation amplitude; AT1: the first applanation time; AV1: the first applanation velocity; AT2: the second applanation time; AV2: the second applanation velocity; HC: the highest concavity; PD: peak distance

In addition, we analyzed the differences of corneal biomechanical parameters between NTG and HTG groups under PGA treatment over time. Among the 111 POAG patients, 68

were NTG patients and the other 43 were HTG (Table 1). There were no statistically significant differences in age, gender, axial length and corneal curvature between these two groups (all $P>0.05$, Table 4). IOP, bIOP and CCT of post-treatment of PGA in NTG group were all statistically significantly lower than those in HTG group (all $P<0.0001$, Table 4). After correcting for age, gender, axial length, corneal curvature, IOP and CCT, AT1 was lower (7.2950 ± 0.2707 in NTG and 7.5889 ± 0.2873 in HTG, $P=0.00011$, Fig. 3A) and AV1 was higher (0.1478 ± 0.0187 in NTG and 0.1314 ± 0.0191 in HTG, $P=0.00002$, Fig. 3B) in NTG group compared to that in HTG group with statistically significant differences (Table 5).

Table 4. Differences in demographic and clinical characteristics between NTG and HTG groups.

	NTG (n=68)	HTG (n=43)	<i>P</i> value
Age (male)	49.15 ± 14.51	46.28 ± 13.50	0.292
Gender	41 (60.3%)	27 (62.8%)	0.843
Axial length	25.52 ± 1.81	25.74 ± 1.70	0.374
Corneal curvature	7.76 ± 0.22	7.75 ± 0.27	0.826
IOP	16.05 ± 2.36	18.47 ± 2.36	<0.0001
bIOP	15.37 ± 2.09	16.90 ± 2.10	<0.0001
CCT	537.44 ± 32.13	564.35 ± 27.96	<0.0001

NTG: normal tension glaucoma; HTG: high tension glaucoma; IOP: intraocular pressure; bIOP: biomechanically corrected intraocular pressure; CCT: central corneal thickness

Table 5. Differences in corneal biomechanical parameters between NTG and HTG groups under PGA treatment over time after adjusting for age, gender, axial length, corneal curvature, IOP and CCT.

	NTG (n=68)	HTG (n=43)	<i>P</i> value
DA	1.1070 ± 0.1115	1.0425 ± 0.1248	0.681
AT1	7.2950 ± 0.2707	7.5889 ± 0.2873	0.00011
AV1	0.1478 ± 0.0187	0.1314 ± 0.0191	0.00002
AT2	21.8646 ± 0.6164	21.6138 ± 0.5827	0.173
AV2	-0.2682 ± 0.0580	-0.2551 ± 0.0426	0.709
HC-time	16.8531 ± 0.5389	16.8520 ± 0.8962	0.477
HC-PD	5.0539 ± 0.2704	4.8712 ± 0.3023	0.241
HC-radius	6.5643 ± 0.9992	6.8861 ± 2.5276	0.428

NTG: normal tension glaucoma; HTG: high tension glaucoma; PGA: prostaglandin analogue; IOP: intraocular pressure; CCT: central corneal thickness; DA: deformation amplitude; AT1: the first appplanation time; AV1: the first appplanation velocity; AT2: the second appplanation time; AV2: the second appplanation velocity; HC: the highest concavity; PD: peak distance

Discussion

PGA is the most widely used first-line therapeutic medication for POAG due to its highest effectiveness in decreasing IOP[19] and reducing circadian IOP fluctuations, as well as its convenient dosing and tolerable side effects[20]. However, PGA was found to have some other effects, such as decreasing the thickness of central cornea. Our results showed CCT declined under treatment of PGA over time, which was in accordance with previous studies[21, 22], implying a possible time cumulative effect of PGA on cornea tissue. The mechanisms of CCT reduction are possibly due to the MMPs up-regulation and extracellular matrix degradation stimulated by PGA in the cornea[8, 9, 23].

The cornea is considered to have both viscous and elastic properties[1]. Studies conducted on the ORA showed that IOP decreased and CH increased significantly after topical PGA treatment[24, 25]. Increased CH indicates an increased corneal viscoelastic response[26]. IOP is a significant influencing factor of corneal deformation[1, 27] and should always be taken into account when analyzing corneal biomechanics. Hence, to better elucidate the corneal biomechanical changes with long-term treatment of

PGA and to avoid the influences of IOP sudden decrease on it, baseline Corvis ST measurements, namely those before initiation of PGA treatment, were not analyzed.

In this study, we showed that DA, AT1 and AV1 changed with statistical significances under PGA therapy over time. Since the results were adjusted for age, gender, axial length, corneal curvature, IOP and CCT, it suggested long-term use of PGA might influence the corneal biomechanics directly. Our observation was consistent with an previous observational study, which found CH increased significantly after 6 months treatment of PGA on newly diagnosed POAG patients measured by ORA, and this increase was only significantly correlated with basal IOP but not with the drug induced IOP reduction, suggesting PGA could have a direct effect on cornea biomechanical properties[25].

A more deformable cornea is characterized by reaching the first applanation faster (with shorter AT1 and greater AV1), the second applanation slower (with longer AT2 and lower AV2) and the highest concavity with greater DA[14]. In our study, although not all of the biomechanical parameters reached statistical significances, DA ($\beta=-0.0015$), AV1 ($\beta=-0.0004$) and AT2 ($\beta=-0.0059$) decreased and AT1 ($\beta=0.0089$) increased as PGA treatment time extended after adjusting for potential confounding factors. Based on the meanings of the parameters, our results indicated a less deformable cornea as PGA treatment prolonged.

Our observations were supported by a few previous studies as follows. Hussnain et al observed a significant decrease in CH among medication, laser or surgery treated POAG patients in a retrospective study[28]. They hypothesized that CH decreased over time in POAG patients even though increased in a short term with therapies to reduce IOP[28]. However, the percentages and types of medical treatment were not mentioned in their publication. Another recent prospective study conducted by Meda et al showed that POAG patients with long-term PGA therapy for at least 1 year had significantly lower CH values than those whose PGA were discontinued[12], which indicated that long-term use of PGA might cause CH decrease.

Pathogenesis differences between NTG and HTG have been investigated by many studies. Factors other than IOP probably contribute more to the onset and development of NTG. Interestingly, we found there were statistically significant differences in corneal biomechanical parameters under PGA treatment between NTG and HTG groups. After adjusting for age, gender, axial length, corneal curvature, IOP and CCT, AT1 was shorter and AV1 was greater in NTG than in HTG, which means that corneas in NTG tend to be more deformable compared to those in HTG with the extension of PGA treatment.

To our knowledge, this is the first prospective study investigating the long-term changes of corneal biomechanical properties with chronic use of PGA measured by Corvis ST. However, some of the limitations need to be considered. The patient profile may not necessarily represent the whole population data because of our clinic-based design. Furthermore, the patients had variant follow-up times and different intervals between visits, which could potentially introduce bias into current results.

Conclusions

Our study indicated that long-term treatment of PGA might make cornea less deformable. It should be taken into consideration when analyzing corneal biomechanics in patients with PGA treatment. We speculate the corneal extracellular matrix remodeling may be involved, although the underlying mechanisms remain unknown. It would be interesting for further studies to validate these changes at a molecular level.

Abbreviations

AT1: the first applanation time

AT2: the second applanation time

AV1: the first applanation velocity

AV2: the second applanation velocity

bIOP: biomechanically corrected IOP

CCT: central corneal thickness

CH: corneal hysteresis

Corvis ST: Corneal Visualization Scheimpflug Technology

DA: deformation amplitude

HC: highest concavity

HC: highest concavity

HTG: high tension glaucoma

IOP: intraocular pressure

MMPs: matrix metalloproteinases

NTG: normal tension glaucoma

OCT: optical coherence tomography

ORA: Ocular Response Analyzer

PD: peak distance

PGA: prostaglandin analogue

POAG: primary open angle glaucoma

SD: standard deviation

Declarations

Ethics approval and consent to participate

This research was approved by the Medical Ethics Committee of Eye and ENT Hospital of Fudan University (KY2012001), and adhered to the Declaration of Helsinki. Written informed consents were obtained from all of the participants.

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interest.

Funding

Supported by funds from the National Science Foundation of China [No. 81570887 and No. 81600730]; the Shanghai Committee of Science and Technology [No. 17410712500] and the top priority of clinical medicine center of Shanghai [No. 2017ZZ01020]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors' contributions

YC and XS conceived and designed the study. NW and YY collected the data. YC and NW performed the statistical analysis, interpreted the data and drafted the manuscript. All authors contributed to manuscript revision, read and approved the submitted version and the authorship list.

Acknowledgements

We are grateful to the glaucoma patients who participated in the study.

References

1. Ali NQ, Patel DV, McGhee CN. Biomechanical responses of healthy and keratoconic corneas measured using a noncontact scheimpflug-based tonometer. *Invest Ophthalmol Vis Sci.* 2014; 55: 3651-3659.
2. Liu J, Roberts CJ. Influence of corneal biomechanical properties on intraocular pressure measurement: quantitative analysis. *J Cataract Refract Surg.* 2005; 31: 146-155.
3. Medeiros FA, Weinreb RN. Evaluation of the influence of corneal biomechanical properties on intraocular pressure measurements using the ocular response analyzer. *J Glaucoma.* 2006; 15: 364-370.
4. Sigal IA, Flanagan JG, Ethier CR. Factors influencing optic nerve head biomechanics. *Invest Ophthalmol Vis Sci.* 2005; 46: 4189-4199.
5. Johnson CS, Mian SI, Moroi S, Epstein D, Izatt, J, Afshari NA. Role of corneal elasticity in damping of intraocular pressure. *Invest Ophthalmol Vis Sci.* 2007; 48: 2540-2544.
6. Wells AP, Garway-Heath DF, Poostchi A, Wong T, Chan, KC, Sachdev N. Corneal hysteresis but not corneal thickness correlates with optic nerve surface compliance in glaucoma patients. *Invest Ophthalmol Vis Sci.* 2008; 49: 3262-3268.
7. Congdon NG, Broman AT, Bandeen-Roche K, Grover D, Quigley HA. Central corneal thickness and corneal hysteresis associated with glaucoma damage. *Am J Ophthalmol.* 2006; 141: 868-875.
8. Sen E, Nalcacioglu P, Yazici A, Aksakal FN, Altinok A, Tuna T, et al. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. *J Glaucoma.* 2008; 17: 398-402.
9. Kocabeyoglu S, Mocan MC, Irkec M. Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues. *Indian J Ophthalmol.* 2015; 63: 15-19.
10. Wu KY, Wang HZ, Hong SJ. Effect of latanoprost on cultured porcine corneal stromal cells. *Curr Eye Res.* 2005; 30: 871-879.
11. Chansangpetch S, Panpruk R, Manassakorn A, Tantisevi V, Rojanapongpun P, Hurst CP, et al. Impact of Myopia on Corneal Biomechanics in Glaucoma and Nonglaucoma Patients. *Invest Ophthalmol Vis Sci.* 2017; 58: 4990-4996.
12. Meda R, Wang Q, Paoloni D, Harasymowycz P, Brunette I. The impact of chronic use of prostaglandin analogues on the biomechanical properties of the cornea in patients with primary open-angle glaucoma. *Br J Ophthalmol.* 2017; 101: 120-125.
13. Shin J, Lee JW, Kim EA, Caprioli J. The effect of corneal biomechanical properties on rebound tonometer in patients with normal-tension glaucoma. *Am J Ophthalmol.* 2015; 159: 144-154.
14. Salvetat ML, Zeppieri M, Tosoni C, Felletti M, Grasso L, Brusini P. Corneal Deformation Parameters Provided by the Corvis-ST Pachy-Tonometer in Healthy Subjects and Glaucoma Patients. *J Glaucoma.* 2015; 24: 568-574.
15. Hon Y, Lam AKC. Corneal Deformation Measurement Using Scheimpflug Noncontact Tonometry. *Optom Vis Sci.* 2013; 90: E1-E8.

16. Wang W, Du S, Zhang X. Corneal Deformation Response in Patients With Primary Open-Angle Glaucoma and in Healthy Subjects Analyzed by Corvis ST. *Invest Ophthalmol Vis Sci.* 2015; 56: 5557-5565.
17. Wu N, Chen Y, Yu X, Li M, Wen W, Sun X. Changes in Corneal Biomechanical Properties after Long-Term Topical Prostaglandin Therapy. *PLoS One.* 2016; 11: e0155527.
18. Huseynova T, Waring GO, Roberts C, Krueger RR, Tomita M. Corneal Biomechanics as a Function of Intraocular Pressure and Pachymetry by Dynamic Infrared Signal and Scheimpflug Imaging Analysis in Normal Eyes. *Am J Ophthalmol.* 2014; 157: 885-893.
19. Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. *Acta Ophthalmol.* 2018;96:e277-e284.
20. Konstas AG, Quaranta L, Katsanos A, Riva I, Tsai JC, Giannopoulos T, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. *Br J Ophthalmol.* 2013; 97: 1510-1515.
21. Sawada A, Yamamoto T, Takatsuka N. Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma. *Graefes Arch Clin Exp Ophthalmol.* 2012; 250: 123-129.
22. Lee H, Cho BJ. Long-term effect of latanoprost on central corneal thickness in normal-tension glaucoma: five-year follow-up results. *J Ocul Pharmacol Ther.* 2015; 31: 152-155.
23. Lopilly Park HY, Kim JH, Lee KM, Park CK. Effect of prostaglandin analogues on tear proteomics and expression of cytokines and matrix metalloproteinases in the conjunctiva and cornea. *Exp Eye Res.* 2012; 94: 13-21.
24. Tsikripis P, Papaconstantinou D, Koutsandrea C, Apostolopoulos M, Georgalas I. The effect of prostaglandin analogs on the biomechanical properties and central thickness of the cornea of patients with open-angle glaucoma: a 3-year study on 108 eyes. *Drug Des Devel Ther.* 2013; 7: 1149-1156.
25. Bolivar G, Sanchez-Barahona C, Teus M, Castejon MA, Paz-Moreno-Arrones J, Gutierrez-Ortiz C, et al. Effect of topical prostaglandin analogues on corneal hysteresis. *Acta Ophthalmol.* 2015; 93:e495-498.
26. Jung Y, Park HL, Yang HJ, Park CK. Characteristics of corneal biomechanical responses detected by a non-contact scheimpflug-based tonometer in eyes with glaucoma. *Acta Ophthalmol.* 2017; 95: e556-e563.
27. Tian L, Wang D, Wu Y, Meng X, Chen B, Ge M, et al. Corneal biomechanical characteristics measured by the CorVis Scheimpflug technology in eyes with primary open-angle glaucoma and normal eyes. *Acta Ophthalmol.* 2016; 94: e317-324.
28. Hussnain SA, Alsberge JB, Ehrlich JR, Shimmyo M, Radcliffe NM. Change in corneal hysteresis over time in normal, glaucomatous and diabetic eyes. *Acta Ophthalmol.* 2015; 93: e627-630.

Figures






Figure 1

The changes of IOP (Fig. 1A), bIOP (Fig. 1B) and CCT (Fig. 1C) in POAG patients under PGA treatment over time.







Figure 2

The changes of DA (Fig. 2A), AT1 (Fig. 2B), AV1 (Fig. 2C) and AT2 (Fig. 2D) in POAG patients under PGA treatment over time.




Figure 3

The changes of AT1 (Fig. 3A) and AV1 (Fig. 3B) in NTG and HTG patients under PGA treatment over time.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [rawdata.xlsx](#)